These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 28049952)

  • 1. Time-Series Modeling and Simulation for Comparative Cost-Effective Analysis in Cancer Chemotherapy: An Application to Platinum-Based Regimens for Advanced Non-small Cell Lung Cancer.
    Chisaki Y; Nakamura N; Yano Y
    Biol Pharm Bull; 2017; 40(1):73-81. PubMed ID: 28049952
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.
    Clegg A; Scott DA; Sidhu M; Hewitson P; Waugh N
    Health Technol Assess; 2001; 5(32):1-195. PubMed ID: 12065068
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of Osimertinib as a Second-line Treatment in Patients With EGFR-mutated Advanced Non-Small Cell Lung Cancer in China.
    Guan H; Liu G; Xie F; Sheng Y; Shi L
    Clin Ther; 2019 Nov; 41(11):2308-2320.e11. PubMed ID: 31607559
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-minimization analysis for Portugal of five doublet chemotherapy regimens from two phase III trials in the treatment of advanced non-small cell lung cancer.
    Pimentel FL; Bhalla S; Laranjeira L; Guerreiro M
    Lung Cancer; 2006 Jun; 52(3):365-71. PubMed ID: 16650499
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized phase 2 study of irinotecan plus cisplatin versus gemcitabine plus vinorelbine as first-line chemotherapy with second-line crossover in patients with advanced nonsmall cell lung cancer.
    Han JY; Lee DH; Song JE; Lee SY; Kim HY; Kim HT; Lee JS
    Cancer; 2008 Jul; 113(2):388-95. PubMed ID: 18484595
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness analysis of three regimens using vinorelbine (Navelbine) for non-small cell lung cancer.
    Hillner BE; Smith TJ
    Semin Oncol; 1996 Apr; 23(2 Suppl 5):25-30. PubMed ID: 8610234
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical and cost effectiveness of paclitaxel, docetaxel, gemcitabine, and vinorelbine in non-small cell lung cancer: a systematic review.
    Clegg A; Scott DA; Hewitson P; Sidhu M; Waugh N
    Thorax; 2002 Jan; 57(1):20-8. PubMed ID: 11809985
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The cost-effectiveness of four cisplatin-containing chemotherapy regimens in the treatment of stages III B and IV non-small cell lung cancer: an Italian perspective.
    Palmer AJ; Brandt A
    Monaldi Arch Chest Dis; 1996 Aug; 51(4):279-88. PubMed ID: 8909011
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Paclitaxel plus carboplatin, compared with paclitaxel plus gemcitabine, shows similar efficacy while more cost-effective: a randomized phase II study of combination chemotherapy against inoperable non-small-cell lung cancer previously untreated.
    Chen YM; Perng RP; Lee YC; Shih JF; Lee CS; Tsai CM; Whang-Peng J
    Ann Oncol; 2002 Jan; 13(1):108-15. PubMed ID: 11863090
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Economic analysis of a randomized phase III trial of gemcitabine plus vinorelbine compared with cisplatin plus vinorelbine or cisplatin plus gemcitabine for advanced non-small-cell lung cancer (Italian GEMVIN3/NCIC CTG BR14 trial).
    Reaume MN; Leighl NB; Mittmann N; Coyle D; Hirsh V; Seymour L; Tu D; Shepherd FA; Graham B; Gridelli C; Perrone F; Di Maio M; Bradbury PA; Evans WK
    Lung Cancer; 2013 Oct; 82(1):115-20. PubMed ID: 23962449
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Paclitaxel: a pharmacoeconomic review of its use in non-small cell lung cancer.
    Plosker GL; Hurst M
    Pharmacoeconomics; 2001; 19(11):1111-34. PubMed ID: 11735678
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan.
    Ohe Y; Ohashi Y; Kubota K; Tamura T; Nakagawa K; Negoro S; Nishiwaki Y; Saijo N; Ariyoshi Y; Fukuoka M
    Ann Oncol; 2007 Feb; 18(2):317-23. PubMed ID: 17079694
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multicentre randomised phase III study comparing the same dose and schedule of cisplatin plus the same schedule of vinorelbine or gemcitabine in advanced non-small cell lung cancer.
    Martoni A; Marino A; Sperandi F; Giaquinta S; Di Fabio F; Melotti B; Guaraldi M; Palomba G; Preti P; Petralia A; Artioli F; Picece V; Farris A; Mantovani L
    Eur J Cancer; 2005 Jan; 41(1):81-92. PubMed ID: 15617993
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of chemotherapy for nonsmall-cell lung cancer.
    Dranitsaris G; Cottrell W; Evans WK
    Curr Opin Oncol; 2002 Jul; 14(4):375-83. PubMed ID: 12130919
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Economic evaluation for the US of nab-paclitaxel plus gemcitabine versus FOLFIRINOX versus gemcitabine in the treatment of metastatic pancreas cancer.
    Gharaibeh M; McBride A; Bootman JL; Patel H; Abraham I
    J Med Econ; 2017 Apr; 20(4):345-352. PubMed ID: 27919186
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rationale for non-platinum chemotherapy in advanced NSCLC.
    Murren JR
    Oncology (Williston Park); 2001 Jul; 15(7 Suppl 8):29-34. PubMed ID: 11497229
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-Utility Analysis of First-Line Pemetrexed Plus Cisplatin in Non-Small Cell Lung Cancer in Thailand.
    Permsuwan U; Thongprasert S; Sirichanchuen B
    Value Health Reg Issues; 2020 May; 21():9-16. PubMed ID: 31634796
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of Pembrolizumab for Patients with Advanced, Unresectable, or Metastatic Urothelial Cancer Ineligible for Cisplatin-based Therapy.
    Patterson K; Prabhu V; Xu R; Li H; Meng Y; Zarabi N; Zhong Y; Batteson R; Pellissier J; Keefe S; Grivas P; de Wit R
    Eur Urol Oncol; 2019 Sep; 2(5):565-571. PubMed ID: 31412011
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New chemotherapeutic agents prolong survival and improve quality of life in non-small cell lung cancer: a review of the literature and future directions.
    Bunn PA; Kelly K
    Clin Cancer Res; 1998 May; 4(5):1087-100. PubMed ID: 9607565
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Economic evaluation of a randomized clinical trial comparing vinorelbine, vinorelbine plus cisplatin, and vindesine plus cisplatin for non-small-cell lung cancer.
    Smith TJ; Hillner BE; Neighbors DM; McSorley PA; Le Chevalier T
    J Clin Oncol; 1995 Sep; 13(9):2166-73. PubMed ID: 7666075
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.